3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
870
Carcinoma, Non-Small-Cell Lung
637
Prostatic Neoplasms
516
Multiple Myeloma
443
Neoplasms
425
Leukemia, Myeloid, Acute
380
Lymphoma
357
Melanoma
335
Leukemia
335
Neoplasm Metastasis
322
Lung Neoplasms
308
Lymphoma, Non-Hodgkin
303
Leukemia, Lymphocytic, Chronic, B-Cell
301
Colorectal Neoplasms
282
Ovarian Neoplasms
266
Pancreatic Neoplasms
249
Precursor Cell Lymphoblastic Leukemia-Lymphoma
241
Recurrence
240
Myelodysplastic Syndromes
233
Glioblastoma
212
Hodgkin Disease
201
Lymphoma, Large B-Cell, Diffuse
197
Lymphoma, Follicular
195
Brain Neoplasms
195
Carcinoma, Renal Cell
190
Head and Neck Neoplasms
188
Squamous Cell Carcinoma of Head and Neck
186
Lymphoma, Mantle-Cell
171
Sarcoma
158
Fallopian Tube Neoplasms
139
Interventions
loncastuximab tesirine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Has results
×
Diffuse Large B-Cell Lymphoma Refractory
×
Clear all
NCT03589469
2023-08-29
LOTIS-2
ADC Therapeutics S.A.
Phase 2
Completed
145 enrolled
24 charts
1 FDA